Vaginal Microbicides for the Prevention of HIV Transmission

KARL MALCOLM*, DAVID WOOLFSON, CLARE TONER AND DEBORAH LOWRY

School of Pharmacy, The Queen's University of Belfast, Belfast, BT9 7BL, Northern Ireland, UK

Introduction

The human immunodeficiency virus (HIV) kills more people worldwide than any other infectious disease. Approximately 42 million people, mostly in Africa and Asia, are currently infected with HIV (Figure 3.1), and 5 million new infections occur every year (AIDS Epidemic Update, 2002). It is estimated that 22 million people have died since the first clinical evidence of AIDS (acquired immunodeficiency syndrome) emerged in 1981 (‘Mobilization for Microbicides’, The Rockefeller Foundation). HIV is generally transmitted in one of three ways: through unprotected sexual intercourse, blood-to-blood contact, and mother-to-child transmission. Once the virus has entered the body, it invades the cells of the immune system and initiates the production of new virus particles with concomitant destruction of the immune cells. As the number of immune cells in the body slowly declines, weight loss, debilitation, and eventually death occur due to opportunistic infections or cancers. Although AIDS is presently incurable, highly active antiretroviral therapy (HAART), where a cocktail of potent antiretroviral drugs are administered daily to HIV-positive patients to control the viral load, has resulted in dramatic reductions in HIV-related morbidity and mortality in the developed world (King et al., 2003; Portsmouth et al., 2003).

*To whom correspondence may be addressed (k.malcolm@qub.ac.uk)

Abbreviations: AIDS, acquired immunodeficiency syndrome; CONRAD, Contraceptive Research and Development; DNA, deoxyribonucleic acid; FDA, Food and Drug Administration (US); GRAS, generally recognized as safe; HAART, highly active antiretroviral therapy; HEC, hydroxyethylcellulose; HIV, human immunodeficiency virus; HSV, herpes simplex virus; hu-SCID, human severe combined immunodeficiency; IND, investigational new drug; MAP, mormorica anti-human immunodeficiency virus protein; N9, nonoxynol-9; NIAID, National Institute of Allergies and Infectious Diseases; NNRTI, non-nucleoside reverse transcriptase inhibitor; PMPA, (R)-(9-(2-phosphonomethoxypropyl)adenine; RNA, ribonucleic acid; RT, reverse transcriptase; SDS, sodium dodecyl sulfate; SHIV, simian/human immunodeficiency virus; SIV, simian immunodeficiency virus; STD, sexually transmitted disease; TOPCAD, Topical Prevention of Conception and Disease.
Figure 3.1. Adults and children estimated to be living with HIV/AIDS at the end of 2002 (image used and modified with kind permission from 'Aids Epidemic Update: December 2002, UNAIDS 0.246E').

Over the years, numerous strategies have been proposed to reduce or prevent sexually-acquired HIV infection, including abstinence, monogamy, condom use, reduction in number of sexual partners, and treatment of sexually related infections. Unfortunately, these strategies have had only limited success in controlling the pandemic, and are not always feasible, particularly for women within the developing world. The most obvious solution to stopping the spread of HIV/AIDS is an effective HIV vaccine. However, over two decades into the HIV pandemic, researchers are still struggling with the daunting scientific challenges involved in developing a safe and effective HIV vaccine ('HIV Vaccines', The NIAID Division of AIDS). There are currently three types of HIV vaccines under investigation; subunit vaccines, recombinant vaccines, and DNA vaccines. The ideal HIV vaccine must be inexpensive, easy to store and administer, and must provide a strong, long-lasting immunity against the many different strains of the HIV virus. Although encouraging clinical data is beginning to surface, it is highly unlikely that a HIV vaccine will be available for human use within the next decade.

Given the devastating effects of the HIV/AIDS epidemic, especially within the developing world, other preventative strategies are urgently needed. It has been estimated recently that heterosexual transmission of HIV now accounts for over 90% of adult infections worldwide, and that male-to-female transmission of HIV is eight times more likely than female-to-male transmission (Lamptey, 2002). A clear scientific rationale therefore exists for the development of female-controlled preventative strategies.

The most promising approach is the development of effective vaginal microbicides. These chemical substances have the potential to either prevent or reduce HIV transmission when applied to the vagina prior to intercourse. Although no effective
microbicidal products are presently available, there is currently a massive push to have an effective first-generation microbicide on the market by 2007.

This review will include a brief discussion of the salient features of HIV, the human vagina, and vaginal transmission of HIV, before describing the current state of affairs relating to the scientific and clinical development of the current lead vaginal HIV microbicide candidates.

The human immunodeficiency virus (HIV)

HIV belongs to the genus of retrovirus known as lentivirus, which have genes composed of ribonucleic acid (RNA) molecules. Like all viruses, HIV replicates inside cells. However, unlike many viruses, it does so by using an enzyme called reverse transcriptase to convert the viral RNA into DNA, which can then be incorporated into the host cell’s genome. The virus was first detected, isolated, and shown to be the causative agent in the development of acquired immunodeficiency syndrome (AIDS) by Gallo (Gallo et al., 1984; Popovic et al., 1984; Sarngadharan et al., 1984; Schupbach et al., 1984), Montagnier (Barré-Sinoussi et al., 1983), and Levy (Levy et al., 1984) (Table 3.1).

HIV is a spherical virus of approximately 100 nm in diameter, containing an electron dense core surrounded by a phospholipid bilayer envelope (Figure 3.2). The major HIV proteins associated with the envelope are gp120 and gp41. These function as the viral attachment proteins, binding to the CD4 receptors on certain host cells, and facilitating viral entry. gp120 is a heavily glycosylated glycoprotein, which is bound to the outside of the membrane and is non-covalently attached to the transmembrane protein, gp41. The HIV proviral genome contains gag, pol and env genes, which code for the core proteins, reverse transcriptase and envelope proteins, respectively. On average, 72 copies of the protein Env, containing three to four gp120 and three to four gp41 molecules, exist on the virus surface. Within the envelope of a mature HIV particle is a bullet-shaped core made of 2000 copies of the viral protein, p24. This capsid holds two single strands of HIV RNA that encode for the virus' nine genes – gag (group specific antigen), pol (polymerase), env (envelope), tat (transactivator), rev (regulator of viral expression), vif (viral infectivity), vpr (viral protein R), vpu (viral protein U), and nef (negative-regulation factor). HIV RNA contains long terminal repeats, which control the synthesis of new virions when activated by the host cell or HIV. The core of HIV also includes protein p7, the
HIV nucleocapsid protein, and copies of three enzymes that carry out later steps in the virus's life cycle: reverse transcriptase, integrase, and protease.

There are several, well-defined steps in the replicative cycle of HIV—attachment, fusion, penetration, uncoating, reverse transcription, nuclear importation, integration, assembly of new virions, viral budding, and maturation. Initial attachment of the virus to the host cell involves non-specific interactions between the viral envelope and molecules (such as heparan sulfate proteoglycans, lectins, and various adhesion molecules) on the surface of human cells, followed by a specific interaction between the gp120 protein on the viral envelope, and the CD4 receptor on the surface of the host cell. The gp120/CD4 interaction thereby induces changes in the molecular conformation of chemokine co-receptor proteins on the cell surface (the most important of which are CCR3, CXCR4 and CCR5) (Alkhatib et al., 1996; Choe et al., 1996; Doranz et al., 1996; Drajic et al., 1996; Feng et al., 1996; Zhang et al., 1998), which facilitate further binding of the virus to the cell via these co-receptors. The HIV envelope then fuses with the cell in a process mediated by the gp41 transmembrane protein in the HIV envelope. Once fusion has taken place, and the viral capsid (the inside of the virus which contains the RNA and important enzymes) is released into the host cell, the matrix and capsid proteins of the virus disassemble, resulting in the release of viral RNA into the cell cytoplasm. HIV genes are carried in the two strands of RNA, while the genetic material of human cells is DNA. In order for the virus to infect the cell, a process called 'reverse transcription' must take place, whereby the viral RNA is converted into complementary DNA (cDNA) by the reverse transcriptase enzyme. This new DNA, also known as 'proviral DNA', is then imported into the nucleus, where it undergoes specific cleavages at the 5' and 3' termini before being integrated into the host DNA with the assistance of the viral enzyme integrase. The DNA then synthesizes new viral RNA, which is transported out of the nucleus and translated, in the case of mRNA, or incorporated into new virions, in the case of genomic RNA. Finally, new virus
Figure 3.3. (a) Histology of the vagina showing the mucosa, submucosa and muscularis; (b) non-keratinised stratified squamous epithelium of the vagina; (c) submucosa of the vagina containing abundance of connective tissue and capillaries; (d) the cervix lined by simple, highly columnar epithelium containing mucous cells (images used and modified with kind permission of Rose M. Chute, Biology Department, North Harris College, Houston, Texas, US (http://science.nhmececd.edu/biol/reproductive/vagina.htm)).

particles are assembled. The protein molecules are cut to size by the viral enzyme protease; these smaller proteins serve a variety of functions - some become structural elements of new HIVs, while others become enzymes, such as reverse transcriptase. Once the new viral particles are assembled, they bud off from the host cell, and create new viruses which, once matured, are capable of infecting new cells.
The human vagina

Sexual transmission of HIV to the human female occurs when the virus enters the mucosal tissues of the cervix and/or vagina and infects host lymphocytes, macrophages, and dendritic cells expressing the CD4 protein. A knowledge of the physiology, histology, and ecology of the vagina will therefore be useful in developing an understanding of the mechanistic details of HIV transmission.

The vagina consists of three distinctive tissue layers: the mucosa, the muscularis, and the tunica adventitia (Figure 3.3). A more detailed description of the histological and immunological characteristics of these layers are provided in Table 3.2. The thickness of the vaginal epithelium and the immune cell populations in vaginal tissue have been reported to remain relatively constant during the menstrual cycle (Patton et al., 2000).

Vaginal fluid consists primarily of transudate, which passes through the vaginal wall from the blood vessels. It is mixed with vulval secretions from sebaceous and sweat glands, with minor contributions from Bartholin’s and Skene’s glands (Burgos and de Vargas-Linares, 1978; Deshpande et al., 1992). The fluid then becomes contaminated with cervical mucus and sloughed cells from the vaginal epithelia. Endometrial and oviductal fluids may also contribute to its chemical composition. Vaginal fluids may also contain several enzymes, enzyme inhibitors, protein, carbohydrates, amino acids, alcohols, hydroxy-ketones, and aromatic compounds. The chief component of vaginal fluid is cervical mucus, produced by glandular units within the cervical canal. The amount, composition, and physical characteristics of cervical mucus change with the menstrual cycle, making its production oestrogen-dependent. The mucus is minimal immediately after menstruation, and becomes more transparent, viscous, and elastic prior to ovulation. At the time of ovulation, the amount of cervical secretions further increases, resulting in an increase in the overall volume of vaginal fluid. Consequently, there is an increase in fibrosity, pH, and mucin content, and a decrease in the viscosity, cellularity, and albumin concentration. Previous studies suggest that approximately 6 g of vaginal fluid are produced daily with approximately 0.5–0.75 g present at any one time in the vagina (Lissimore and Currie, 1939; Lapan and Friedman, 1950; Perl et al., 1959; Odeblad, 1964; Dusitsin et al., 1967; Preti et al., 1979; Wagner, 1979; Wagner and Levin, 1980; Godley, 1985; Owen and Katz, 1999).

These physiological parameters will almost certainly have implications for the development of anti-HIV vaginal microbicides. It is also apparent that any drug intended for application as a vaginal microbicide will require at least some solubility in aqueous vaginal fluid, to a degree dependent on its potency, while, in certain cases, also requiring sufficient lipid solubility to permit uptake across the viral and/or vaginal epithelial membranes. Also, changes in the volume and physical make-up of the fluid, particularly in response to sexual excitement, may further influence drug release/solubility/permeation characteristics (Masters and Johnson, 1966).

The vaginal fluid in healthy mature women is maintained at a pH of between 3.5 and 5 by the commensal microorganism Lactobacillus acidophilus, which produces lactic acid from glycogen contained in the sloughed mature cells of the vaginal mucosa. The acidic nature of the vaginal fluid is of great practical importance as it offers natural resistance to the colonization of various microorganisms (Graves et al.,
Table 3.2. Histological description of the human vagina

<table>
<thead>
<tr>
<th>Layers</th>
<th>Sublayers</th>
<th>Histological description</th>
<th>Immune cells present in normal vaginal mucosa*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucosa</td>
<td>Epithelium 15–200 nm</td>
<td>Approximately 25 layers (menstrual cycle dependent) of non-keratinised, stratified, squamous cells (Patton et al., 2000; Burgos and de Vargas-Linares, 1978); five cell types identified: (i) basal – small, typically columnar or squamous in shape with small nuclei, very little cytoplasm, and microvilli present on cell surface; (ii) parabasal – polygonal in shape, similar in size and structure to basal cells; (iii) transitional; (iv) intermediate – largest cells, exhibit microvilli, abundant in cytoplasm and glycogen; (v) superficial – outermost layer during follicular phase of cycle</td>
<td>T8 lymphocytes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>T4 lymphocytes</td>
</tr>
<tr>
<td></td>
<td>Lamina propria</td>
<td>Loose, highly vascularised connective tissue (extremely rich in blood vessels and lymphatics)</td>
<td>Langerhans cells</td>
</tr>
<tr>
<td>Submucosa</td>
<td>Connective tissues made of collagen and elastic fibres, and blood vessels</td>
<td></td>
<td>Macrophages</td>
</tr>
<tr>
<td>Muscularis</td>
<td>Smooth muscle fibres arranged in an outer longitudinal layer and an inner circular layer</td>
<td></td>
<td>Neutrophils</td>
</tr>
<tr>
<td>Adventitia</td>
<td>Thin, fibrous layer composed of dense sheath of collagen and elastic fibres; contains blood vessels, lymph vessels and nerves</td>
<td></td>
<td>Plasma cells</td>
</tr>
</tbody>
</table>

* Patton et al., 2000

1980; Sturn and Zanen, 1984; Croughan and Behbehani, 1988; Nagy et al., 1991; Pettit et al., 1999; Sparling, 1999). The pH of vaginal fluid rises during menstruation, but it may also increase after periods of frequent acts of coitus as both vaginal transudate, formed during coitus, and ejaculate are alkaline. Elevated pH has been associated with increased transmissibility of HIV infection (Martin et al., 1985; Ongradi et al., 1990; O’Connor et al., 1995). Physiologically, the anterior fornix of the vagina has the lowest pH, which gradually rises toward the vestibule. Intravaginal pH may also be affected by the presence of cervical mucus, which has a pH in the range 6.5 to 9, and by the amount of lubricating vaginal secretions. These changes could influence the solubility, uptake, and release profile of pH-sensitive substances within the vagina.

Biochemical activity in the vagina may also be an important factor that may affect the stability of certain microbicidal substances. The basal layer of the vaginal epithelium has a high activity of enzymes found in the citric acid cycle, in fatty acid metabolism, and in 17-ketosteroidogenesis, e.g. succinic dehydrogenase, diaphorase, acid phosphotase, β-glucuronidase, and phosphoamidase. The outer cell layers
of the vagina contain β-glucuronidase, acid phosphatase, and smaller quantities of α-naphthylesterase, diaphorase, phosphoamidase, and succinic dehydrogenase (Yu and Chien, 1982).

Vaginal transmission of HIV

Several excellent reviews on the sexual/vaginal transmission of HIV have been published (Osmond, 1998; Miller and Shattock, 2003), and therefore only a brief overview will be provided here.

Although HIV may be transmitted by several non-sexual modes, including mother-to-child transmission, transfusion of contaminated blood, and drug injection, the current AIDS pandemic is largely driven by heterosexual/vaginal transmission, which accounts for some 90% of new HIV-1 infections globally (Royce et al., 1997). This is despite the fact that vaginal fluid is the least infectious of body fluids (attributed to the relatively low concentration of CD4+ cells in vaginal fluid compared to other fluids).

It is well documented that vaginal intercourse can transmit HIV either from male-to-female or female-to-male (Padan et al., 1991, 1997; European Study Group, 1992; Mastro et al., 1994; Nicolosi et al., 1994). However, in the absence of other risk factors, such as sexually transmitted diseases, men are two to three times more likely to transmit HIV to women than vice versa (Peterman et al., 1988; European Study Group, 1992), and eight times more likely when sexually transmitted diseases are taken into consideration (Padan et al., 1997). Several facts help in explaining this observation, including: 1) a larger exposed area of susceptibility to infection in women (vagina, cervix, and uterus) compared with men (head of the penis, exposed urethra); 2) women are exposed to a larger quantity of infectious fluid (ejaculate, typically 1.5 to 5 ml) than men (vaginal fluids, typically >1 ml (reviewed in Owen and Katz, 1999)); 3) the concentration of HIV virions in vaginal fluid tends to be less than in semen; and 4) women retain the secretions within the body after sex while men are only exposed during the sexual act. Semen has been shown to contain both free infectious HIV-1 and HIV-1-infected cells (Mermin et al., 1991; Pidney and Anderson, 1991; Vernazza et al., 1994, 1996; Zhang et al., 1998), and thus transmission might occur by cell-free and/or cell-associated HIV modes. Studies of SIV transmission in Rhesus macaques suggest that cell-associated virus does not contribute significantly to sexual transmission (Miller, 1992). Instead, free virus binds to CD4+ Langerhans cells and macrophages in the genital mucosa before being transported to the lymph nodes. Given that CD4-expressing Langerhans cells, dendritic cells, and macrophages are also present in the human vaginal epithelia, it is possible that these are the main target cells for HIV infection via heterosexual vaginal intercourse in the human female. However, a number of studies have demonstrated that HIV infection of epithelial cells does not occur, but is instead limited to cells within the sub-epithelial mucosa, strongly suggesting that establishment of HIV infection requires epithelial penetration (Pomerantz et al., 1988; Miller et al., 1992; Nuovo et al., 1993; Palacio et al., 1994; Spira et al., 1996). The current consensus is that at least two main routes are available for HIV to cross the vaginal epithelium – transepithelial migration of infected Langerhans cells, and penetration of the virus through damaged epithelial tissue (Miller and Shattock, 2003).
Figure 3.4. Diagram illustrating the proposed four major mechanisms by which HIV can be transported across the vaginal epithelium and initiate infection in the submucosal tissue.

(Figure 3.4). Damage to the vaginal epithelium is detected in most women following consensual intercourse (Novell et al., 1984), and would potentially provide direct viral access to susceptible T cells, dendritic cells, and macrophages in the vaginal lamina propria.

There is also evidence to suggest that the cervix might be more susceptible to HIV than vaginal tissue, a consequence of its fragility, the fact that it is commonly compromised by a number of sexually transmitted diseases, and, like the vagina, the presence of specific HIV receptors (Howell et al., 1997; Zhang et al., 1999; Moench et al., 2001). The importance of the cervix as a site for HIV infection has been demonstrated in experiments in which rhesus macaques were infected vaginally with HIV. Cervical cells were observed to be infected by day 3, while the vaginal mucosa was not infected until day 12 (Zhang et al., 1999). In contrast, it has also been reported that cervical ectopy, an immature area of the cervix lined by fragile columnar rather than more protective squamous epithelium, is not independently associated with HIV infection (Moscicki et al., 2001).

In the absence of hard in vivo data, researchers are still uncertain as to the type of cells that initially become infected in the reproductive tract of women after exposure to HIV – in chronically HIV-1-infected women, T cells, macrophages, and Langerhans cells in cervical tissue are all infected. Indeed, as already alluded to, one of the major problems in studying HIV transmission is the lack of a suitable in vitro model. For example, in studies employing the simian immunodeficiency virus (SIV)–rhesus monkey model, Langerhans cells (Spira et al., 1996), CD4+ T cells (Zhang et al.,...
and dendritic cells (Spira et al., 1996; Hu et al., 2000) have all been implicated as the first cell type to become infected upon inoculation with SIV. However, more recent studies using a cervical tissue-derived organ culture model to study HIV transmission across the mucosal surface (designed to more closely mimic the human in vivo situation) have shown that memory CD4+ T cells were first to become infected (0.2, 2.7, and 2.3% after 6, 24 and 96 h, respectively) followed by macrophages (0.8 and 1.2%, respectively) and dendritic cells (0.1, 0.7%, respectively) (Gupta et al., 2002). Such a model may prove useful in the preclinical screening of potential vaginal microbicides.

An increased risk of HIV susceptibility and infectiousness in females has also been positively associated with a wide range of cervicovaginal infections (Royce et al., 1997), including *Neisseria gonorrhoeae* (Martin et al., 1998), *Chlamydia trachomatis* (Laga et al., 1993), *Candida* infection (Martin et al., 1998), and bacterial vaginosis (Martin et al., 1998). Progesterone therapy and oral contraception have also been correlated with increased risk of vaginally-acquired HIV (Ungchusak et al., 1996; Mostad et al., 1997; Martin et al., 1998).

Vaginal microbicides

Vaginal microbicides are chemical substances, or formulations thereof, that prevent, or at least reduce, the transmission of sexually transmitted diseases, including HIV, when applied to the human vagina prior to intercourse. Several characteristics typify the ideal vaginal HIV microbicide — broad spectrum of activity; activity against both cell-free and cell-associated HIV; minimal systemic absorption; non-toxic to vaginal tissue; retention of activity in the presence of semen; activity over a broad pH range (typically pH 3–8); available in contraceptive and non-contraceptive forms; compatibility with condoms; retention in the vagina over prolonged periods of time; low cost; long shelf life; ease of use/acceptability/patient compliance.

The first potential microbicide formulations to be evaluated contained the non-ionic surfactant, nonoxynol-9. It has long been employed as the active ingredient in various marketed spermicides and lubricating gels, and has GRAS (generally recognized as safe) status. Although various initial studies suggested that nonoxynol-9 was effective *in vitro* against a wide range of sexually transmitted microorganisms through disruption of the viral/bacterial membrane (Singh et al., 1972; Hicks et al., 1985; Judson et al., 1989), its surfactant characteristics were also shown to be responsible for damaging the vaginal epithelium, resulting in an increased risk of HIV transmission (Kreiss et al., 1992; Roddy et al., 1998; Stephenson, 2000; Fichorova et al., 2001; Rustomjee and Adboul Karim, 2001; Wilkinson et al., 2002).

Although a vaginal microbicide may potentially act at any stage of the HIV replicative cycle, it is preferable to disrupt the cycle as early as possible. For this reason, the most promising microbicides currently being evaluated are attachment/binding/fusion/entry inhibitors, inhibitors of reverse transcription, or compounds/formulations that enhance the natural vaginal defence mechanisms (Figure 3.5).

There are currently 34 products in preclinical development, 15 in Phase I safety trials, 4 in Phase II expanded safety and preliminary effectiveness trials, and 3 in Phase III trials (Table 3.3, Figure 3.6).

To date, little thought has gone into optimizing vaginal microbicide formulations...
Figure 3.5. Mechanisms of action of vaginal microbicides.

Figure 3.6. Development profile for vaginal microbicides.
<table>
<thead>
<tr>
<th>Mechanism of microbicide action</th>
<th>Product type/compound</th>
<th>Other name/trade name (developer)</th>
<th>Clinical status</th>
<th>Cont.*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Compounds that kill or inactivate HIV</strong></td>
<td><strong>See later section of table</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acidic buffers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotic peptides</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipids</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monoclonal antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peroxidases/peroxides</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plant extracts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Surfactants/detergents/lipids</strong></td>
<td>Prunee (polyherbal oil)</td>
<td>(Inst. Res. &amp; Reprod., India)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gossypol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzalkonium chloride</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C31G (Savvy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonoxynol-9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Octoxynol-9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium dodecyl sulfate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium lauryl sulfate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Inhibitors of HIV binding/entry</strong></td>
<td><strong>B69 (modified beta-lactoglobulin)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peptides/proteins</td>
<td>Cyanovirin-N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T-20 (gp41 fusion inhibitor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carrageenan (seaweed derivative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellulose sulfate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sulfated polysaccharides</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Inhibitors of HIV replication**

**Non-nucleoside reverse transcriptase inhibitors**
- Calanolide A/B
- DABO
- Nevirapine
- TMC-120
- UC-781
- 3TC
- AZT
- ddI
- Tenofovir (PMPA)
- Doxovir (CTC-96)

**Nucleoside reverse transcriptase inhibitors**
- Sarawak MediChem (Indenix Pharmaceuticals)
  Preclinical
- Viramune
  Preclinical
- Dapivirine (Tibotec-virco)
  Preclinical
- Lamivudine
  NC
- Zidovudine
  NC
- Didanosine
  NC
- Viread™ (Gilead)
  Phase I
- (Redox Pharmaceutical Corp.)
  Preclinical

**Protease inhibitors**
- Buffergel™ (ReProtect LLC)
  Phase II/III
- AcidForm™ (TOPCAD, GMP)
  Phase I
- Virosheild™
  Phase II
- e.g. retrocyclin (RC-100)
  e.g. squalamine

**Enhancers of natural vaginal defence mechanisms**
- Bioadhesive acidic aqueous gel/Carbomer 974P formulation
- Lactobacillus crispatus
- CD4-expressing Lactobacillus
- Protegrins
- Defensins
- Magainins
- Gramicidin
- Plantibodies™
- Hydrogen peroxide/peroxidases
- Estrogens
- e.g. estradiol

**Acidity regulators**
- MAP30 (Memordica anti-HIV protein) (NY University School of Medicine)
  NC
- GAP31 (Gelonium anti-HIV protein) (NY University School of Medicine)
  NC
- Cellulose acetate phthalate
- Monocaprin with PAVAS
- Naphthalene urea derivatives (Mt. Sinai Medical Centre)

**Maintenance of vaginal ecology**

**Antibiotic peptides**

**Monoclonal antibodies**

**Other**

**Multiple mechanisms**

**Antiviral proteins**

**Others**

**Herbal substances**
- Alatavir
- Kolvirin
- Pokeweed antiviral protein
- Prancepn
- Tinosporin
- Anionic dendrimers
- Porphyrins and protoporphyrins
- Sodium dimenel ol acid ether
- Zinc glutamate gel
- Cobalt containing redox complex
- n-cyclodextrin
- Gossypol

**Uncharacterized**

* C – contraceptive; NC – non-contraceptive.
for effective delivery within and distribution throughout the vagina. The vast majority of candidate microbicides are formulated in traditional semi-solid topical gels or creams for the purposes of clinical evaluation. However, the advantages of such gel systems, such as their inexpensiveness and ease of manufacture, need to be considered alongside their inherent disadvantages, which include relatively poor retention in the vagina (even for so-called ‘bioadhesive’ formulations), messiness in their application, requirement for applicator use, poor user acceptability, and interference with coitus (Woolfson et al., 2000). In order to provide protection, semi-solid formulations are most likely to require application prior to every act of intercourse, which is also likely to lead to poor user compliance. A number of alternative formulations for the delivery of vaginal microbicides are currently being evaluated, such as controlled-release intravaginal rings (Woolfson et al., 1999, 2003; Malcolm et al., 2001, 2003a,b; Malcolm, 2003), akin to those currently being marketed for contraception (Nuvaring®) and hormone replacement therapy (Estring®, Femring®).

The remainder of this review describes in more detail the scientific literature relating to 19 microbicidal substances, presented in alphabetical order, that are currently being evaluated for the prevention of heterosexual transmission of HIV. In order to provide the reader with a broad perspective of the current state of play within the field, compounds have been selected representing all stages of the research and development pipeline.

### Acidform

*Acidform™* is an aqueous-based, bioadhesive, acid-buffering gel formulation designed to keep the vagina acidic in the presence of semen. The gel, which has been developed by the Programme for Topical Prevention of Contraception and Disease (TOPCAD), consists of water, gelling agents, buffer salts, humectants, and preservatives in a proprietary mixture buffered to pH 3.55. All the ingredients are ‘generally recognized as safe’ (GRAS) except for one, which is currently used in a number of marketed vaginal products. The low pH of Acidform, in addition to having the potential to inactivate HIV and other pathogens, is also spermicidal, immobilizing 100% of the spermatozoa even when diluted 10-fold before addition to semen (Zaneveld et al., 1996). Like many gel-based vaginal microbicide formulations, Acidform may also create a physical barrier that inhibits the passage of pathogens into the vaginal and cervical epithelia. A Phase I clinical study designed to evaluate the vaginal tolerance of Acidform has demonstrated that it does not irritate the vaginal epithelium (Amaral et al., 1999). However, when Acidform was co-formulated with 2.5 and 5.0% w/w nonoxynol-9, vaginal erythema and/or abrasions were observed in 50% of women after two days use, and in 100% after seven days use (Amaral et al., 1999). The *in vitro* acid-buffering, bioadhesive, viscosity and stability characteristics of Acidform have been evaluated, and compared to those of other marketed vaginal gels (Garg et al., 2001). The study not only indicated that Acidform has excellent semen-buffering ability, but that its high viscosity and bioadhesive characteristics should ensure that it will coat and be retained within the vagina.
B69

The New York Blood Centre has shown that chemical modification of bovine beta-lactoglobulin, a major protein of milk and whey, resulted in the generation of a potent inhibitor of infection by HIV, including clinical isolates. The compound, designated B69 or 3HP-β-LG, is a biological candidate compound for chemical barriers against vaginal, oral, and rectal HIV transmission. Laboratory tests have shown that B69 blocked at nanomolar concentrations the binding to CD4 of human (HIV) and simian (SIV) immunodeficiency virus surface glycoproteins and monoclonal antibodies specific for the HIV binding site on CD4, and inhibited infection by HIV-1, including primary virus isolates, by HIV-2 and by SIV (Neurath et al., 1996).

It has been reported previously that B69, suspended in phosphate-buffered saline and administered prior to and after intravaginal inoculation with SIV, was effective in preventing SIV transmission in 50% of the female rhesus monkeys tested (Wyand et al., 1999). Studies have shown that B69 is not irritating to vaginal tissues and has no deleterious effects on bacteria corresponding to the natural vaginal flora. In vitro inhibition of the herpes simplex virus has also been indicated by B69 (Manson et al., 2000).

BufferGel

BufferGel™ (ReProtect) is a spermicidal and microbicidal gel formulation (pH 3.9) based on Carbomer 974P, a synthetic, high molecular weight, pharmaceutical grade poly(acrylic acid) (Figure 3.7) cross-linked with a polyalkenyl polyether.

Carbomers are a class of poly(acrylic acid)s used in a wide range of cosmetic and pharmaceutical applications, at concentrations up to 50% w/w. The carboxylic acid functional groups in the Carbomer are capable of maintaining the protective acidic environment of the vagina in the presence of alkaline semen (Olmsted et al., 2000; Maguire et al., 2001; Zeitlin et al., 2001) without adversely affecting the Lactobacillus species normally responsible for pH maintainece (Clarke et al., 2002). Encouragingly, vaginal BufferGel use also significantly reduces the number of anaerobic pathogens present, whose associated disease states may have implications for HIV transmission; for example, the number of women presenting Gardnerella vaginalis, associated with bacterial vaginosis, was reduced by up to 87% after once-daily vaginal application of BufferGel for 14 days (van de Wijgert et al., 2001; Clarke et al., 2002). The pH required for HIV inactivation (and indeed many other sexually transmitted disease microorganisms) has been reported in different studies to be between 4 and 5.8 (Ongradi et al., 1990; O'Connor et al., 1995). Five millilitres

![Structure of polyacrylic acid.](image-url)
of BufferGel is capable of buffering twice its volume of semen to a pH of 5.0, equivalent to approximately three times the average ejaculate volume (Olmsted et al., 2000). In addition to its ability to directly inactivate sperm, HIV, and other microorganisms, the bioadhesive BufferGel formulation may also create a viscid physical barrier that inhibits the passage of pathogens into the vaginal and cervical epithelium. The safety of BufferGel in regard to vulvar, vaginal, and cervical epithelial toxicity has already been demonstrated in HIV/STD negative women in a multi-centre, international Phase I clinical trial (Mayer et al., 2001; van de Wijgert et al., 2001). Enrolment is currently in progress for a multinational, multiproduct Phase II/III effectiveness trial (see reference section – HPTN 0350).

The excellent mucosal safety profile of Carbomers and their widespread inclusion in various pharmaceutical formulations make BufferGel an obvious gel base for the formulation of other HIV microbicides. For example, UC-781, a potent experimental non-nucleoside, reverse transcriptase inhibitor currently being evaluated as a vaginal microbicide, has been formulated in BufferGel, and its efficacy in preventing HIV-1 transmission through cervical tissue evaluated (Zussman et al., 2003).

C31G

C31G is an equimolar mixture of two amphoteric, surface-active molecules: N-n-dodecyl-N,N-dimethylamine-N-oxide (C12-N-oxide) and N-n-dodecyl-N,N-dimethyl-amine-N-glycine (C12-N-betaine) (Figure 3.8). It has broad spectrum antibacterial, antiviral, and antifungal activity (Corner et al., 1988; Calis et al., 1992; Thompson et al., 1996; Wyrick, et al., 1997; Krebs et al., 1999; Birnie et al., 2000). However, the surfactant mixture is not active against non-enveloped viruses, such as the sexually transmitted human papillomaviruses, which have been implicated in the genesis of cervical cancer (Malamud et al., 1998; Howett et al., 1999). The antimicrobial, and presumably antiviral, activity of alkyl betaines and alkyl dimethylamine oxides have been reported to increase with increasing alkyl chain lengths up to approx. 15 carbon atoms, such that minimum inhibitory concentrations were directly correlated with critical micelle concentrations (Birnie et al., 2000).

In vitro anti-HIV activity has been demonstrated for C31G in several studies. It has been reported to have greater capacity for inactivating both cell-free and cell-associated HIV-1 than nonoxynol-9 (N9) or sodium dodecyl sulfate (SDS) (Krebs et al., 1999). For example, in studies to assess the effect of surfactant concentrations on the ability of various HIV strains to infect HeLa-CD4-LTR-β-gal (HCLB) cells, C31G, N9, and SDS inactivated at the 0.00625% concentration level were shown to
Table 3.4. Self-reported symptoms, results of colposcopic evaluation and product acceptability in women using 5 ml daily applications for 7 days of various gel formulations (Ballagh et al., 2002)

<table>
<thead>
<tr>
<th>Symptoms of vaginal/vulvar irritation</th>
<th>Microbicide formulation</th>
<th></th>
<th>Microbicide formulation</th>
<th></th>
<th>Microbicide formulation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.2% C31G HEC gel</td>
<td>2% N9 gel (Gynol II)</td>
<td>HEC-only gel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>80%</td>
<td>45%</td>
<td>50%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heat/burning</td>
<td>80%</td>
<td>25%</td>
<td>5%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New lesions: non-applicator-related</td>
<td>45%</td>
<td>50%</td>
<td>20%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serious lesions: non-applicator-related</td>
<td>20%</td>
<td>10%</td>
<td>0%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Would use if effective contraceptive</td>
<td>25%</td>
<td>35%</td>
<td>55%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

have inactivated 84, 67 and 24% of HIV-1 IIIB (Tropic) virions, respectively, 78, 44, and 23% of HIV-1 BaL (M tropic) virions, respectively, and 100, 72, and 23% of HIV 89.6 (dual tropic) virions, respectively, compared to an untreated control. At this concentration, cell viability was decreased to approximately 85% for C31G and N9, compared to 95% for SDS. Complete viral inactivation was achieved in all strains at C31G concentrations of 0.025% and above, but this was associated with a concomitant decrease in cell viability. The results demonstrate that all three agents could function either solely or in combination at concentrations that provide effective viral inactivation and low levels of cytotoxicity. In a subsequent study by the same investigators, primary human vaginal keratinocytes (cells found within the vaginal epithelium) were five times more sensitive to N9 than either C31G or SDS during continuous 48-hr exposure (Krebs et al., 2000). In a more realistic multiple exposure mode, cells were considerably more sensitive to C31G than N9 or SDS at lower concentrations within the range tested. Furthermore, in time-sensitivity studies, exposure to C31G for 18 hrs decreased cell viability to a greater extent than exposure to N9 or SDS for at least 24 hrs. These concentration and time-sensitivity considerations are clearly important factors impacting the in vivo efficacy of vaginal micobicides. Other in vitro experiments have been performed in which cell lines of human immune and epithelial origin are used as surrogate markers for primary cells to evaluate the effects of micobicides on cell metabolism, membrane composition, and integrity, and the effects of cell-type, proliferation, and differentiation on micobicide sensitivity (Krebs et al., 2002).

In the first Phase I human trial of C31G (60-women, randomized, double-blind, 7-day tolerance study), a C31G hydroxyethylcellulose (HEC) gel formulation, previously shown to exhibit antimicrobial properties in vitro (Birnie et al., 2001), presented significant differences in the incidence of vaginal symptoms and colposcopic findings, compared to a positive control nonoxynol-9 gel (Gynol II) and a negative control HEC gel (Table 3.4) (Ballagh et al., 2002). The most common complaint was a burning sensation in the vagina, reported by 80% of C31G users. It is also clear that the active agents, C31G and N9, caused increased incidence of epithelial disruption in these formulations, compared to the HEC-only gel, whether reported in the form of lesions, oedema, or erythema. Given the physicochemical
characteristics of surfactant molecules, and in particular their ability to solubilize lipids, such damage to vaginal epithelia is not wholly unexpected. However, the study also highlights two additional issues pertinent to the development of vaginal microbicide formulations. First, much more research needs to be conducted into the design and use of vaginal applicators; the results of this and other studies have reported a significant incidence of applicator-related epithelial damage. Second, the results reiterate the generally poor acceptability of gel-based vaginal formulations, associated with leakage, messiness, and partner acceptability.

In a follow-up Phase I study, designed to assess the tolerability and user acceptability of five reformulated C31G gel/cream formulations, a marked decrease in the incidence of self-reported symptoms, compared with that of the 1.2% C31G HEC formulation, was reported (Bax et al., 2002). For example, the best tolerated and most accepted formulation amongst the 105 women enrolled, a 1.0% C31G poloxamer gel formulation (poloxamers are co-polymers of propylene and ethylene glycols), caused a heating/burning sensation in only 13% of users, compared with 80% for the HEC formulation. It is unlikely that the improved acceptability of the co-polymer product is related solely to the decreased C31G concentration or the decreased vaginal dose used in this study (3.5 ml cf. 5.0 ml). However, it will be imperative to conduct both colposcopy studies and imaging studies with the co-polymer gel to evaluate the integrity of the vaginal epithelium during use, and to ensure that the reduced dose volume is sufficient to provide protective coverage within the vagina.

**Carrageenan**

Carrageenan is a linear polysaccharide, derived from red seaweed, and composed of repeating sulfated and non-sulfated D-galactose and 3,6-anhydro-D-galactose units joined by alternating $\alpha(1\rightarrow3)$, $\beta(1\rightarrow4)$ glycosidic linkages. Its polymeric structure and various sources and extraction methods ensure that many structural variations exist; for the sake of simplicity, three main types are defined – kappa, iota, and lambda carrageenans – which are idealized molecules assigned definitive structures (Figure 3.9). Most seaweeds produce a range of structural variations, rather than these idealized structures.

Carrageenan is the most active sulfated polysaccharide against HIV (PearcePratt and Phillips, 1996). In its native form, it has a (weight average) molecular weight of $\sim$2 million, although it is usually prepared in low molecular weight form to enhance absorption. It is stable, even at elevated temperatures, is not degraded by bacteria, and has been used for hundreds of years as a thickener in foods, and as an emulsifier in topical creams and lotions. Carrageenan compounds are on the US Food and Drug Administration’s list of GRAS (generally recognized as safe) products for consumption and topical application. This classification gives carrageenan-based formulations a number of advantages, including the need for fewer standard preclinical tests for regulatory approval, and a greater likelihood that they could be made available widely and easily.

Carraguard™ (formerly known as PC-515), a 3% w/w aqueous gel formulation of carrageenan, is the Population Council’s lead candidate microbicide. It has been shown to block infection by HIV, HSV-2, HPV and *N. gonorrhoeae* both *in vitro* and
in vivo (Zacharopoulos and Phillips, 1997; Bourne et al., 1999a; Maguire et al., 2001). A carrageenan solution, however, provided no protection in a mouse model against Chlamydia trachomatis, a sexually transmitted infection implicated in increased risk of HIV infection (Achilles et al., 2002). Phase I human safety studies of related carrageenan compounds (PC-213 and PC-503), and data from pilot studies of Carraguard (PC-515), have shown that carrageenan is not harmful when used vaginally (Elias et al., 1997; Coggins et al., 2000). Interim safety data from the Population Council’s expanded safety, acceptability, and preliminary effectiveness trials also show Carraguard to be safe and acceptable when used for up to 12 months. A Phase III effectiveness trial of Carraguard is scheduled to begin in 2004, and will last approximately four years. If it is shown to be effective, a New Drug Application will be filed with the US Food and Drug Administration and regulatory authorities in the other countries where it will be available.

Polymer-drug conjugates of kappa-carrageenan have also been synthesized using a succinate spacer to covalently link 3'-azido-3-deoxythymidine (AZT, a potent, FDA-approved anti-HIV agent) to the polymer backbone (Vliege et al., 2002) (Figure 3.10). Synergism between the carrageenan and AZT was demonstrated when MT-4 cells were preincubated with the conjugate prior to HIV-1 infection, although a threshold loading of AZT was required to achieve this effect. Although such conjugated molecules have not yet been considered for vaginal application, they could offer many advantages, including: i) increased activity through synergism; ii) decreased drug toxicity; iii) controlled release potential; and iv) delay in emergence of drug-resistant strains.
Cellulose acetate phthalate

Cellulose acetate phthalate (CAP) is a high molecular weight compound (average molecular weight, $M_n \approx 60000$) (Figure 3.11) commonly used as an enteric film coating material or a matrix binder for tablets and capsules (Lee, 1994). It is a promising microbicide candidate for prevention of infection by sexually transmitted disease pathogens, including HIV-1 (Neurath et al., 1999). CAP inactivates HIV-1 and blocks the co-receptor binding site on the virus envelope glycoprotein gp120, while leaving the site for the primary cellular receptor CD4 accessible (Deng et al., 1996; Neurath et al., 2001). CD4 was shown to inhibit HIV-1 infection by two mechanisms: reversible blockage of virus binding to receptors, and irreversible inactivation of virus activity.

When formulated in a vehicle, a micronized form of CAP has been shown to inactivate HIV-1, herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), cytomegalovirus, Neisseria gonorrhoeae, Trichomonas vaginalis, Haemophilus ducreyi,
and *Chlamydia trachomatis* in vitro. Another advantage of CAP is that it does not appear to affect lactobacilli, part of the natural vaginal flora that contributes to resistance to STDs (Neurath et al., 1999).

### Cellulose sulfate

Cellulose sulfate, which has a backbone consisting of (1→4) linked glucose units with adjacent trans-hydroxyl groups (Gohdes et al., 1997) (Figure 3.12), is being developed as a vaginal microbicidal by the Programme for the Topical Prevention of Conception and Disease (TOPCAD, Chicago) in collaboration with the Contraceptive Research and Development (CONRAD) programme (Washington DC), and is currently in clinical trials. The mechanism by which cellulose sulfate effects microbial activity against STD’s could be either by binding to the infectious agent or by binding to the target cell, thus preventing successful infection of susceptible host cells or tissues (Christensen et al., 2001).

In addition to exhibiting in vitro antimicrobial activity against sexually transmitted pathogens (Mauck et al., 2001), cellulose sulfate has been found to be also a contraceptive in rabbits, both when a 0.1% formulation is mixed with sperm prior to vaginal administration, or when a 5% formulation is applied vaginally prior to sperm introduction (Anderson et al., 2000b).

Ushercell is a high molecular weight cellulose sulfate envisioned for vaginal use primarily in the prevention of heterosexual transmission of HIV infection and other sexually transmitted diseases (Anderson et al., 2002). HIV-1 inhibition by Ushercell correlates with earlier data obtained with low molecular weight forms of this polymer (Mizumoto et al., 1988; Yamamoto et al., 1990), although Ushercell activity has been reported to be greater (Anderson et al., 2002). The data provide convincing evidence that, in vitro, Ushercell is highly effective against HIV. Ushercell has a broad spectrum of antimicrobial activity in vitro. Inhibited microbes include HIV (IC<sub>50</sub> values range from 3 to 78 μg/ml), HSV-1 (IC<sub>50</sub> = 59 ng/ml) and HSV-2 (IC<sub>50</sub> = 24 ng/ml), *Neisseria gonorrhoeae* (IC<sub>50</sub> = 2 μg/ml), and *Chlamydia trachomatis* (IC<sub>50</sub> = 78 μg/ml). Importantly, Ushercell does not inhibit growth of the beneficial vaginal bacteria, *Lactobacillus gasseri*, at 5 mg/ml. These results suggest that the antimicrobial effects of Ushercell are selective, and not likely mediated by non-specific cytotoxic mechanisms (Anderson et al., 2002).

Currently, a vaginal contraceptive containing 100 mg cellulose sulfate and 230 mg nonoxynol-9 is marketed in Germany under the name A-Gen53. Clinical studies
of this product report a high degree of safety, with a slight burning sensation as the only reported side effect (Martínez Sausor and Royo, 1984).

**Cyanovirin-N**

Cyanovirin-N is an 11 kDa protein, consisting of a single 101 amino acid chain containing two intrachain disulfide links (important for HIV activity) between its four cysteine residues (*Figure 3.13*) (Gustafson et al., 1997). Isolated from the cyanobacterium (blue-green alga), *Nostoc ellipsosporum* (Boyd et al., 1997), cyanovirin is a highly potent virucidal agent that has generated interest as a lead candidate for the prevention and chemotherapy of HIV infection by preventing viral entry into host cells (Henderson, 1997). Its antiviral activity is mediated through high-affinity interactions with N-linked high-mannose oligosaccharides found on gp120 viral surface envelope glycoproteins (Esser et al., 1999; O’Keefe et al., 2000; Bolmstedt et al., 2001). It is interesting to note that the Ebola virus, which is also susceptible to inhibition by cyanovirin-N, contains similar oligosaccharide constituents on its surface envelope, and thus further implicates these carbohydrate moieties as viral molecular targets (Barrientos et al., 2003).

**Dextran sulfate**

*Figure 3.14. Structure of dextran sulfate.*
Dextran is an α(1→6)-linked, glucose polymer containing approximately 5% branching through α(1→3)-linkages (Rankin and Jeanes, 1954). The size of the dextran polymer can vary, and hence the sulfated derivatives of dextran that are produced have variable molecular weights. Dextran sulfate is a heparin-like polysaccharide containing approximately 17% sulfur, with up to three sulfur groups per glucose molecule (Araki et al., 2001) (Figure 3.14).

Polyanionic sulfated polysaccharides, such as dextran sulfate, contain negatively charged glycoprotein surfaces which affect both viral binding and uncoating. Dextran sulfate potently inhibits the absorption of HIV to CD4+ cells. Synthetic peptides, negatively charged glycoproteins, and polysaccharides, as well as antisera and monoclonal antibodies raised against gp120, bind to the neutralizing domains of gp120, and prevent HIV-1 entry into the target cells (Batinic and Robey, 1992). It has been demonstrated that negatively charged sulfated polysaccharides, such as dextran sulfate, bind to the positively charged side chain groups of amino acids of gp120 to inhibit HIV-1 replication in vitro (Baba et al., 1988, 1990). Dextran sulfate has also been shown to block the attachment of HIV particles to T lymphocytes (Baba et al., 1988; Mitsuya et al., 1988; Schols et al., 1989).

The activity of dextran sulfate against various strains of HIV has been shown to be dependent upon the molecular weight of the dextran sulfate (Busso and Resnick, 1990; Witvrouw et al., 1991). Although no marked differences in inhibition of HIV were observed, for dextran sulfates within the weight average molecular range of 3000–500 000, significant differences were observed when the molecular weight was decreased to 1000.

**Docosanol**

![Figure 3.15. Structure of docosanol.](image)

*n*-Docosanol, \([\text{CH}_3(\text{CH}_2)_{21} \text{OH}]\), is a 22-carbon saturated primary alcohol (Figure 3.15) with antiviral activity against a broad spectrum of lipid-enveloped viruses in vitro, including HSV-1, HSV-2, CMV, VZV, HHV-6, and HIV-1 (Katz et al., 1991, 1994; Pope et al., 1998; Scolaro et al., 2001). The compound has been shown to lack any of the toxic, mutagenic, and teratogenic properties normally associated with most other antiviral therapeutic drugs currently available, and is therefore under investigation as a possible anti-HIV microbicide (Katz et al., 1991). Studies have demonstrated that *n*-docosanol is not directly virucidal in nature, but that cells pre-treated with the drug are rendered resistant to infection by many lipid-enveloped viruses (Katz et al., 1991, 1994; Marcelletti et al., 1996). Similarly, it has been shown that non-enveloped viruses, such as the poliovirus, are not susceptible to the inhibitory action of *n*-docosanol (Katz et al., 1991). These observations suggest that the inhibitory effect of *n*-docosanol is related to the viral entry process of lipid-enveloped viruses into their target cells.

Inhibition studies have demonstrated that *n*-docosanol has the ability to inhibit HIV-1 in cultures of peripheral blood mononuclear cells (PBMCs) in a dose-dependent
manner (Marcelletti et al., 1996). The drug demonstrated a 50% effective concentration (EC50) of ~10 mM, and preincubation of the PBMCs with n-docosanol was shown to significantly increase the anti-HIV activity of the drug. In contrast, n-docosanol added to the PBMC cultures at the same time as the HIV-1 infection did not demonstrate any significant HIV inhibition. Additional studies of an n-docosanol topical cream have clearly demonstrated that prevention of SIV mac251 vaginal transmission in rhesus macaques is possible (Miller et al., 1995). These observations indicate that n-docosanol may be useful as a prophylactic treatment to prevent the transmission of HIV in human candidates and, therefore, the drug warrants further investigation as a potential topical therapy, particularly in light of its low toxicity and broad inhibitory effect against most lipid-enveloped viruses.

**Human monoclonal antibody b12**

There has been much speculation as to the potential efficacy of antibodies in preventing mucosal transmission of HIV. Several recent studies have demonstrated that both intravenous (Parren et al., 2001) and vaginal administration (Veazey et al., 2003) of broadly neutralizing monoclonal antibody b12 (MAb b12) specific for HIV-1 gp120 provides dose-dependent protection to progestogen-treated macaques vaginally challenged with the chimeric simian/human immunodeficiency virus (SHIV-162P4). (SHIV, like HIV, employs the chemokine CCR5 receptor to enter cells, and is therefore a useful model for HIV-1 transmission.) In the later study, initial in vitro experiments showed that MAb b12 could inhibit infection of macaque peripheral-blood mononuclear cells, immature human dendritic cells, and human cervical explants. In vivo, 3 of 12 rhesus macaques became infected after having received b12 vaginally, either in a gel or saline formulation, compared with 12 out of 13 that received a control human monoclonal antibody. The protective effect was also shown to be dose-dependent.

**MAP30**

MAP30 (Momordica Anti-human immunodeficiency virus Protein) is a 30 kDa single-stranded plant protein from the bitter melon, Momordica charantia, possessing anti-HIV (Lee-Huang et al., 1990, 1995a; Bourinbaiar and Lee-Huang, 1995; Huang et al., 1999), anti-HSV (Bourinbaiar and Lee-Huang, 1996), and anti-tumour potential (Lee-Huang et al., 1995b; Huang et al., 1999). It seems to inhibit multiple stages of the viral life cycle, on acute infection as well as replication in chronically infected cells. Recombinant MAP30 (re-MAP30) has been shown to inhibit HIV-1 to the same extent as its native counterpart, natural MAP30 (nMAP30) (Lee-Huang et al., 1995b), and exhibits little toxicity to the uninfected viral target cells and other normal human cells. re-MAP30, like nMAP30, is also active in topological inactivation of viral DNA, inhibition of viral DNA integration, and cell-free ribosome inactivation. The cloning and expression of the gene encoding biologically active re-MAP30 provides an abundant source of homogeneous material for clinical investigations, as well as structure-function studies. Early studies have also demonstrated that MAP30 enhances the anti-HIV activity of the weak HIV antagonists, dexamethasone and indomethacin, suggesting that MAP30, in combination with low
pharmacological doses of these drugs, may improve the efficacy of anti-HIV therapy. The non-spermicidal properties of MAP30 have also been reported – the protein has no effect on the motility or vitality of human sperm cells over a dose range of 0.1 to 100 mg/ml, a range that encompasses the HIV-I/HSV inhibitory doses (Schriebel et al., 1999). The structural basis for MAP30's biological activities has been investigated by solution state ¹H, ¹³C and ¹⁵N nuclear magnetic resonance spectroscopies, and demonstrates similarity in secondary structure and P-sheet topology with those of the ricin A chain (Wang et al., 1999).

PMPA (tenofovir)

![Structure of PMPA](image)

Figure 3.16. Structure of PMPA (tenofovir).

PMPA ((R)-9-(2-phosphonomethoxypropyl)adenine) (Figure 3.16) is an acyclic adenosine nucleotide analogue reverse transcriptase inhibitor being developed by Gilead Sciences (Foster City, California, USA). It is the parent compound of tenofovir disoproxil fumarate (Viread), the orally bioavailable prodrug FDA approved in 2001 for treatment of HIV infection. Tenofovir is phosphorylated by adenylyl kinase to the pharmacologically active metabolite, tenofovir diphosphate, which inhibits viral replication by competing with deoxyadenosine 5'-triphosphate for incorporation into newly synthesized DNA. Upon incorporation, tenofovir diphosphate results in chain termination.

Applied intravaginally, tenofovir may be absorbed by cells in the vaginal epithelium, therefore potentially blocking local viral replication once infection has occurred. In a study of 4 rhesus macaques challenged intravaginally with simian immunodeficiency virus (SIV) and administered intravaginal tenofovir gel (10% w/w) at 24 hours before and 0, 24, 48 hours after challenge, 100% of the treated animals remained free of evidence of systemic SIV infection. In an additional study, 1% w/w tenofovir gel administered 24 hours before, 15 minutes before, and 24 hours after a single intravaginal inoculation of SIV resulted in protection of 4 out of 5 rhesus macaques. Sixty per cent protection was achieved in a third group of macaques which received only a single application of 1% w/w PMPA gel 15 minutes before challenge (Bischofberger et al., 1996; Miller et al., 1996). Post-exposure prophylaxis for 28 days with PMPA, initiated after 12 to 72 hours, has also been demonstrated in macaques after intravaginal exposure to HIV-2 (Otten et al., 2000). Systemic infection was not evident in the 12 and 36 hour groups, while breakthrough infection was detected in the 72 hour group 16 weeks post-exposure. The results clearly demonstrate that early intervention after high risk sexual exposure may prevent infection. A Phase I Safety and Acceptability Study is currently in progress with 0.3% and 1.0% w/w tenofovir gel formulations.
Polystyrene sulfonate

![Chemical structure of polystyrene sulfonate](image)

Figure 3.17. Structure of the sodium salt of polystyrene sulfonate.

Several studies have demonstrated the in vitro activity of polystyrene sulfonate, or its sodium salt (Figure 3.17), against a range of vaginal pathogens including *Chlamydia trachomatis* (Herold et al., 1999; Anderson et al., 2000a), *Gardnerella vaginalis* (associated with bacterial vaginosis) (Herold et al., 1999; Simoes et al., 2002), *Neisseria gonorrhoeae* (Anderson et al., 2000a), bovine papillomavirus (Christensen et al., 2001), and herpes simplex virus (Herold et al., 1999). Importantly, the growth of *Lactobacillus* species normally present in the vagina was not inhibited; lactobacilli break down glycogen in the vaginal epithelial cells to lactic acid, and thus maintain the acidic environment in which HIV and other sexually transmitted disease microorganisms cannot survive. However, in a mouse model, polystyrene sulfonate provided no protection against *Chlamydia trachomatis* inoculation (Achilles et al., 2002).

Praneem

Praneem is an intravaginal cream or pessary formulation containing extracts of neem leaves (*Azadirachta indica*), *Sapindus mukorossi* oil, and mentha citrate oil, and having both spermicidal and antimicrobial activity. Unlike nonoxynol-9 formulations, however, it does not damage the vaginal mucosa. Numerous studies have reported the spermicidal characteristics of Praneem (Garg et al., 1993, 1994; Talwar et al., 1995; Raghuvanshi et al., 2001) – each individual component is inherently spermicidal, but their combination results in a synergistic effect, enhancing spermicidal activity eight- to twelve-fold relative to the single components. Praneem has also been demonstrated to act as a broad spectrum microbicide, killing a wide range of genital pathogens (Talwar et al., 1995; Talwar, 2001). It has been reported to inhibit the growth in culture of clinical isolates of *Candida albicans*, *Candida krusei*, *Candida tropicalis*, various strains of *Escherichia coli* and *Neisseria gonorrhoeae*, and HIV-1. In addition, vaginal application of the cream and pessary formulations in progestin-sensitized mice prevented lesions and vaginal transmission of HSV-2 and *Chlamydia trachomatis* (Talwar et al., 2000).
PRO 2000

![Chemical Structure of PRO 2000](image)

*Figure 3.18. Structure of naphthalene sulfonate polymer PRO 2000.*

PRO 2000 is a stable, colourless, odourless, water-soluble naphthalene sulfonate polymer synthesized by the condensation reaction between 2-naphthalene sulfonic acid and formaldehyde. The polymerization mechanism produces polymer molecules having a broad range of molecular weights; PRO 2000 is defined as the fraction having molecular weight 4000–5000 Daltons \((n = \text{approx. } 20), \text{Figure 3.18}\) (Rusconi *et al*., 1996; Bourne *et al*., 1999b). The formaldehyde condensation reaction produces a range of methylene substitution patterns on the naphthalene moiety. PRO 2000 has been shown to effectively block binding of recombinant HIV envelope glycoprotein gp120 to recombinant CD4 at nanomolar concentrations \((IC_{50} = 400 \text{ ng/ml})\) (Rusconi *et al*., 1996). Similarly, PRO 2000 has been shown to inhibit infection in a wide range of HIV isolates in a variety of cell types (Rusconi *et al*., 1996). PRO 2000 has also been evaluated in a cervical explant model, where a concentration of 100 \(\mu\text{g/ml}\) (400 times less than that currently proposed for intra-vaginal use – see following two paragraphs) efficiently blocked HIV infection under conditions that mimic both compromised epithelial integrity and inflammatory conditions (Greenhead *et al*., 2000).

The ability of PRO 2000 to protect against HSV-2 infection and disease onset in a mouse model has also been demonstrated (Bourne *et al*., 1999b). PRO 2000 Carbopol 1382 gel formulations \((0.5\% \text{ and } 4\% \text{ w/w})\) were shown to protect against infection in a concentration-dependent manner \((81\% \text{ and } 100\% \text{ protection, respectively})\) when administered 20 seconds prior to viral inoculation; a similarly administered placebo gel offered protection in only 18\% of mice. Although such studies demonstrate the efficacy of the microbicide, administration of a microbical gel 20 seconds before viral challenge is unlikely and impractical in a human context; microbicidal formulations are more likely to be used minutes or hours before intercourse. Thus, the authors have also reported on the effect of time of vaginal administration of a 4\% w/w PRO 2000 gel on efficacy. The results show that efficacy decreased from 100\% to 92\% to 58\% with gel administered 5, 15 and 30 minutes, respectively, prior to inoculation.

Two clinical studies have evaluated the safety and tolerability of PRO 2000 gel formulations in sexually active HIV-negative, sexually inactive HIV-negative, and
sexually inactive HIV-positive women (van Damme et al., 2000; Mayer et al., 2003). In the earlier Phase I study, where the 4%, 0.5% w/w or placebo gel was administered once daily for 2 weeks, cervicovaginal abrasion was observed colposcopically in 3 out of 73 subjects (two in the 4% and one in the placebo), and genital ulceration was not observed at all, thereby demonstrating the topical acceptability of the formulations. Furthermore, plasma levels of PRO 2000 showed no evidence of systemic absorption. In the latter study, 2% and 4% w/w PRO 2000 vaginal gel formulations applied once or twice daily were evaluated for epithelial disruption. Almost three-quarters of the women had at least one adverse effect, although most of these were classified as mild. Not surprisingly, more adverse effects were reported for users of the 4% twice daily gel. Phase II/III efficacy trials are currently being planned.

### SPL7013

SPL7013 is a dendrimer molecule being developed by an Australian company, Starpharma, that has been shown to possess high potency against a range of sexually transmitted disease pathogens, including HIV, HSV, hepatitis B and chlamydia (Bourne et al., 2000). (Dendrimers are novel, spherical-shaped macromolecules having a fractal-type architecture radiating out from a central core.) In recent in vitro studies, SPL7013 has prevented cell infection when challenged with various HIV-1 and HIV-2 strains isolated from HIV-positive patients (Witvrouw et al., 2000). In order to assess the ability of the dendrimer to prevent HIV/SIV and chlamydia infection, two clinical studies using a macaque model and a gel formulation of the dendrimer are currently ongoing in the US, while a Phase I human trial is planned for the near future, subject to an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA).

### Sulfated polysaccharides

It is well understood that sexual transmission of HIV is mediated to vaginal epithelia via mononuclear cells found in semen and cervical–vaginal secretions. The first critical step in this process is cell–cell adhesion. Therefore, compounds that prevent this adhesion process may be effective when administered vaginally in reducing the probability of infection. The potential of sulfated polysaccharides in this regard was first described in the late 1980s (Ito et al., 1987; Nakashima et al., 1987; Baba et al., 1988), and since then several such compounds (Table 3.3) have been investigated for activity against a range of enveloped viruses (PearcePratt and Phillips, 1993, 1996; Lynch et al., 1994; Witvrouw and de Clercq, 1997; Yamada et al., 1997, 2000; Bourne et al., 1999b; Coggins et al., 2000; Schaefer and Krylov, 2000; Haslin et al., 2001; Maguire et al., 2001; Achilles et al., 2002; Neurath et al., 2002). The negatively charged functionalities associated with the sulfate groups in these polysaccharides are responsible for inhibiting the binding of the virions to the cell by shielding the positively charged sites of amino acids in the V3 loop of the viral envelope glycoprotein (gp120) (Schols et al., 1990; Witvrouw and de Clercq, 1997); cell-to-cell adhesion/fusion is prevented in a similar fashion (Baba et al., 1990). Information relating to specific sulfated polysaccharides can be found elsewhere in this review.
TMC-120

![Structure of TMC-120](image)

Figure 3.19. Structure of TMC-120.

TMC-120 (a dianilinopyrimidine derivative, Figure 3.19) is a second-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI), currently being developed by Tibotec-Virco Belgium, with high potency against wild-type HIV-1 ($EC_{50} = 0.3$ ng/ml, $CC_{50} = 0.9$ mg/ml, selectivity index = 2400). Its antiretroviral activity in HIV-positive patients has been tested in a randomized double blind Phase I/II study (Pauwels, 2001), in which 43 participants received 50 or 100 mg twice daily or placebo as monotherapy for 7 days, followed by triple antiretroviral therapy with a number of new antiretroviral agents. The mean viral load decrease at day 8 was $-1.44$ log in the 50 mg group and $-1.51$ log in the 100 mg group. The only adverse events reported were somnolence or insomnia, which occurred in three individuals. Activity against strains with NNRTI resistance mutations K103N, Y181C, and G190A/S is below 10-fold resistance, compared to wild type. When passaged against a laboratory strain, resistance to the TMC compounds emerged either more slowly, or not at all, compared to efavirenz and nevirapine, the two NNRTIs in common use at present. Non-GLP vaginal irritation experiments in rabbits have shown no irritation, and systemic absorption was only detected with very high concentrations (1M concentration). The potential effectiveness of TMC120 as a vaginal microbicide has recently been demonstrated in the humanized severe combined immunodeficient (hu-SCID) mouse model (di Fabio et al., 2003), where intravaginal application of a TMC-120 gel formulation administered 20 minutes prior to non-invasive vaginal challenge with cell-associated HIV prevented systemic infection. Importantly, the work provides the first in vivo evidence that a vaginally-administered non-nucleoside reverse transcriptase inhibitor is capable of acting as a HIV microbicide.

UC-781

![Structure of UC-781](image)

Figure 3.20. Structure of the non-nucleoside reverse transcriptase inhibitor UC-781.
UC-781 (N-[4-chloro-3-(3-methyl-2-butenyloxy)phenyl]-2-methyl-3-furancarboxythioamide) (Figure 3.20) belongs to a class of thioracetamidic derivatives and is a potent and selective non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 in cell culture (Balzarini and de Clercq, 1996). It is a tight-binding inhibitor of the HIV-1 reverse transcriptase enzyme at low non-toxic concentrations (Buckheit et al., 1997), and is currently the only NNRTI with this unique tight-binding characteristic, making it an ideal anti-HIV microbicidal candidate. The hydrophobic nature of the UC-781 molecule means it is able to readily transverse the HIV-1 membrane envelope and penetrate the capsid core, where it binds rapidly to the RT. Once bound, UC-781 does not readily dissociate from the enzyme, even after excess drug is removed and is effectively trapped within the virion (Borkow et al., 1997; Zussman et al., 2003). This tight-binding property means that UC-781 shows considerable potential as a virucidal agent for the prevention of the sexual transmission of HIV from an infected to a non-infected individual.

Exposure of HIV-1 chronically infected cells to UC-781 has been shown to attenuate the infectivity of nascent virus subsequently produced by the UC-781 treated cells, even after the removal of exogenous drug, therefore preventing any further cell-to-cell transmission by the virus. Similarly, incubation of uninfected lymphocytic cells with UC-781 renders these cells refractory to subsequent HIV-1 infection for several days, even after the removal of residual drug. Only short-term exposure to UC-781 is necessary to rapidly exert this potent, long-term microbicidal activity (Borkow et al., 1997, 2002; Parniak, 2001).

Studies of a 5% UC-781 lipophilic Replens gel administered vaginally in rabbit models showed no signs of irritation, inflammation, or toxicity to vaginal mucosa or epithelial tissue (Balzarini et al., 1998). This is of particular importance, as irritation and damage to the epithelial tissue and mucosal membranes have been shown to facilitate the sexual transmission of the virus. In addition, the drug was found to lack any significant inhibitory activity against normal vaginal flora (Candida and Lactobacillus strains) and other closely related RNA and DNA viruses, such as HIV-2 or simian immunodeficiency virus. These observations are not surprising, due to the high pathogen specificity and selectivity of UC-781 for HIV-1 reverse transcriptase (Balzarini et al., 1998). In the same study, UC-781 has also been shown to be both temperature and pH stable over prolonged periods of time. UC-781 incorporated into a Replens gel formulation was stable up to 50°C over a one month time period. At pH 2.3, a pH value well below that of the normal human vagina (pH 3.5), UC-781 demonstrated no loss of antiviral activity after a 4-hr exposure period (Balzarini et al., 1998).

Conclusions

There is much optimism in the microbicide field that an effective, first-generation vaginal microbicide will be available within the next five years to reduce/prevent the heterosexual transmission of HIV. The optimism appears to be well founded. Not only have great strides been made in understanding the mechanisms of sexual transmission of the virus, but a wealth of new, potent microbicidal candidates are also being rationally developed and evaluated in infectivity models that closely mimic the situation in humans. The importance of developing an effective microbicide product
soon has also been brought into sharp focus in the light of recent disappointing Phase III clinical results relating to Vaxgen’s gp120 vaccine. However, many challenges remain. Most of the current research and evaluation is being carried out by small biotech companies, not-for-profit research entities, university research groups, and other public sector organizations. Large pharma are reluctant to get involved, at least in these early stages of development, owing to concerns regarding the potential market for microbicides (The Economics of Microbicide Development), regulatory uncertainty, and concerns over liability and safety. Also, the implementation of ethical clinical trials, where condom use is promoted alongside microbicide use, necessitates very large numbers of volunteers to provide statistically relevant data, which translates into significantly higher costs. The challenge of ensuring availability of a clinically effective microbicide product to the women who need it is also a very real one. While many questions remain to be answered, it is clear that vaginal microbicides offer the most optimistic short-term answer to the AIDS pandemic. A clear, focused, and multi-disciplinary strategy is imperative to ensure that they are made available to the women who need them as soon as possible.

References


BALZARINI, J. AND DE CLERCQ, E. (1996). The thioorcarboxanilides UC-10 and UC-781 have an
additive inhibitory effect against human immunodeficiency virus type 1 reverse transcriptase
and replication in cell culture combined with other antiretroviral drugs. Antiviral Chemistry
and Chemotherapy 8, 197–204.

UC-781 as a virucidal agent. Aids 12, 1129–1138.


BARrientos, L.G., O’KEEFE, B.R., BRAY, M., ANTHONY, S., GRONENBORN, A.M. AND BOYD,

immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic

BAX, R., DOUVILLE, K., MCCORMICK, D., ROSENBERG, M., HIGGINS, J. AND BOWDEN, M.

betaines and N-alkyl-N,N-dimethylamine oxides from semisolids. Antimicrobial Agents and
Chemotherapy 44, 2514–2517.

BIRNIE, C.R., MALAMUD, D., THOMULKA, K.W., SCHWARTZ, J.B. AND SCHNAARE, R.L.
(2001). Antimicrobial and diffusional correlation of N-alkyl betaines and N-alkyl-N,N-

macaques chronically infected with SIV. Ninth International Conference on Antiviral
Research, Fukushima, May 19–24.

targeting N-linked, high mannose glycans in an oligosaccharide-specific manner. Molecular
Pharmacology 59, 949–954.

BORKOW, G., BARNARD, J., NGUYEN, T.M., BELMONT, A., WAINBERG, M.A. AND PARNIAK,
M.A. (1997). Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection:
retroviral activity of UC-781, a thioorcarboxanilide non-nucleoside inhibitor of HIV-1

infectivity of HIV type 1 from epithelial cells pre-treated with a tight-binding non-nucleoside
reverse transcriptase inhibitor. AIDS Research and Human Retroviruses 18, 711–714.

inflammatory drugs, dexamethasone and indomethacin, by MAP30, the antiviral agent from
bitter melon. Biochemical and Biophysical Research Communications 208, 779–785.

proteins MAP30 and GAP31 against herpes simplex virus infection in vivo. Biochemical and
Biophysical Research Communications 219, 923–929.

BOURNE, K.Z., BOURNE, N., REISING, S.F. AND STANBERRY, L.R. (1999a). Plant products as
topical microbicide candidates: assessment of in vitro activity against herpes simplex virus

The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model.
Journal of Infectious Diseases 180, 203–205.

(2000). Dendrimers, a new class of candidate topical microbicides with activity against herpes
simplex virus infection. Antimicrobial Agents and Chemotherapy 44, 2471–2474.

a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope


**Esser, M.T., Morii, T., Sattentau, Q.J., et al.** (1999). Cyanovin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. *Journal of Virology* **73**, 4360–4371.


Vaginal microbicides for the prevention of HIV transmission


Vaginal microbicides for the prevention of HIV transmission


Current Topics in Medicinal Chemistry 3, 1458–1466.

of vaginal secretions caused by sexual arousal. Fertility and Sterility 32, 47–54.

PUDNEY, J. AND ANDERSON, D.J. (1991). Orchitis and human immunodeficiency virus type 1-
infected cells in reproductive tissues from men with the acquired immune deficiency

Spermicidal and contraceptive properties of Praneem polyherbal pessary. Indian Journal of
Medical Research 113, 135–141.


controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually


RUSCONI, S., MOONIS, M., MERRILL, D.P. ET AL. (1996). Naphthalene sulfonate polymers with
CD-4 blocking and anti-human immunodeficiency virus type 1 activities. Antimicrobial
Agents and Chemotherapy 40, 234–236.

to? HIV Clinical Trials 2, 185–192.

Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of
patients with AIDS. Science 224, 506–508.

SCHAEFFER, D.J. AND KRYLOV, V.S. (2000). Anti-HIV activity of extracts and compounds from

demonstrate whether anti-HIV agents inhibit virion binding to T4+ cells. Journal of Acquired
Immunodeficiency Syndromes 2, 10–15.

polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein
expressed by T cells persistently infected with HIV-1. Virology 175, 556–561.

antiviral agents, MAP30 and GAP31, are not toxic to human spermatozoa and may be useful
in preventing the sexual transmission of human immunodeficiency virus type 1. Fertility and
Sterility 72, 686–690.

SCHUPBACH, J., POPOVIC, M., GILDEN, R.V., GONDA, M.A., SARNAIADHARAN, M.G. AND
retroviruses (HTLV-III) associated with AIDS. Science 224, 503–505.

The antiviral drug docosanol as a treatment for Kaposi’s sarcoma lesions in HIV type
1-infected patients: a pilot clinical study. AIDS Research and Human Retroviruses 17, 35–
43.

(polyethylene sulfonate and cellulose sulfate) inhibit Gardnerella vaginalis and anaerobes
commonly associated with bacterial vaginosis. Antimicrobial Agents and Chemotherapy 46,
2692–2695.

preparation providing both prophylaxis against venereal disease and other genital infections
and contraception: II. Effect in vitro of vaginal contraceptive and non-contraceptive
preparations on Treponema pallidum and Neisseria gonorrhoeae. British Journal of Venereal
Disease 48, 57–64.

McGraw-Hill.


**Witvrouw, M., Schols, D., Andre, G. et al.** (1991). Antiviral activity of low-MW dextran sulfate (derived from dextran MW 1000) compared to dextran sulfate samples of higher MW.
Antiviral Chemistry and Chemotherapy 2, 171–179.

WITVROUW, M., FIKKERT, V., PLUYMERS, W. ET AL. (2000). Polymeric (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrate) in the virus replicative cycle. Molecular Pharmacology 58, 1100–1108.


